Literature DB >> 1560003

Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices.

M A Lemmon1, J M Flanagan, J F Hunt, B D Adair, B J Bormann, C E Dempsey, D M Engelman.   

Abstract

Specific side-by-side interactions between transmembrane alpha-helices may be important in the assembly and function of integral membrane proteins. We describe a system for the genetic and biophysical analysis of these interactions. The transmembrane alpha-helical domain of interest is fused to the C-terminus of staphylococcal nuclease. The resulting chimera can be expressed at high levels in Escherichia coli and is readily purified. In our initial application we study the single transmembrane alpha-helix of human glycophorin A (GpA), thought to mediate the SDS-stable dimerization of this protein. The resulting chimera forms a dimer in SDS, which is disrupted upon addition of a peptide corresponding to the transmembrane domain of GpA. Deletion mutagenesis has been used to delineate the minimum transmembrane domain sufficient for this behavior. Site-specific mutagenesis shows that a methionine residue, previously implicated as a potential interfacial residue, can be replaced with other hydrophobic residues without disrupting dimerization. By contrast, rather conservative substitutions at a valine on a different face of the alpha-helix disrupt dimerization, suggesting a high degree of specificity in the helix-helix interactions. This approach allows the interface between interacting helices to be defined.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560003

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  142 in total

1.  Polar side chains drive the association of model transmembrane peptides.

Authors:  H Gratkowski; J D Lear; W F DeGrado
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association.

Authors:  M M Javadpour; M Eilers; M Groesbeek; S O Smith
Journal:  Biophys J       Date:  1999-09       Impact factor: 4.033

3.  Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium.

Authors:  G Zimmer; F Oeffner; V Von Messling; T Tschernig; H J Gröness; H D Klenk; G Herrler
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

4.  A notable cleavage: winding up with beta-amyloid.

Authors:  K S Kosik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  Influence of the C-terminus of the glycophorin A transmembrane fragment on the dimerization process.

Authors:  M Orzáez; E Pérez-Payá; I Mingarro
Journal:  Protein Sci       Date:  2000-06       Impact factor: 6.725

6.  Specificity in transmembrane helix-helix interactions can define a hierarchy of stability for sequence variants.

Authors:  K G Fleming; D M Engelman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

7.  Contribution of energy values to the analysis of global searching molecular dynamics simulations of transmembrane helical bundles.

Authors:  Jaume Torres; John A G Briggs; Isaiah T Arkin
Journal:  Biophys J       Date:  2002-06       Impact factor: 4.033

8.  A putative molecular-activation switch in the transmembrane domain of erbB2.

Authors:  Sarel J Fleishman; Joseph Schlessinger; Nir Ben-Tal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

9.  The transmembrane domain of the DnaJ-like protein DjlA is a dimerisation domain.

Authors:  C M Toutain; D J Clarke; J A Leeds; J Kuhn; J Beckwith; I B Holland; A Jacq
Journal:  Mol Genet Genomics       Date:  2003-01-31       Impact factor: 3.291

10.  Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.

Authors:  C L Burke; D F Stern
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.